Thomas Capelli, DO
Internal Medicine · Kilauea, HINPI 1487698155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.
Across 228 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$607
- GSK$535
- Pfizer$495
- Boehringer Ingelheim$486
- Takeda Pharmaceuticals U.S.A., Inc.$277
- plus $1K from 21 others
Across 1 payment — averaging $26,332 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$26K
What the payments were for
- Food & beverage$4,83199%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $1,038 |
| AstraZeneca | 30 | $607 |
| GSK | 27 | $535 |
| Pfizer | 40 | $495 |
| Boehringer Ingelheim | 19 | $486 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $277 |
| Lundbeck LLC | 8 | $234 |
| Amarin Pharma, Inc. | 8 | $151 |
| Insmed, Inc. | 1 | $138 |
| Exact Sciences | 4 | $113 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $107 |
| Novo Nordisk | 5 | $107 |
| Kowa Pharmaceuticals America, Inc. | 5 | $96 |
| Nestle Healthcare Nutrition Inc. | 4 | $81 |
| Amgen | 3 | $64 |
| Dexcom, Inc. | 2 | $48 |
| Lilly USA, LLC | 2 | $43 |
| UCB, Inc. | 1 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Nevro Corp. | 1 | $30 |
| Boston Scientific | 1 | $26 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
How this compares
$4,866 in reported general payments places this provider in the 85th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 67 | $66,986 |
| EliquisApixaban | 47 | $58,489 |
| JardianceEmpagliflozin | 31 | $43,385 |
| OzempicSemaglutide | 32 | $43,217 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $32,198 |
| TrulicityDulaglutide | 12 | $15,417 |
| Rosuvastatin Calcium | 134 | $4,796 |
| Paroxetine Hcl | 17 | $4,547 |
| Atorvastatin Calcium | 232 | $4,351 |
| ValacyclovirValacyclovir Hcl | 57 | $3,019 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 43 | $2,919 |
| Losartan Potassium | 168 | $2,377 |
| Tamsulosin Hcl | 97 | $2,239 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 70 | $2,212 |
| Celecoxib | 73 | $2,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $495 | $58,48947 claims |
| Boehringer IngelheimJardiance | $486 | $43,38531 claims |
| Novo NordiskOzempic | $107 | $43,21732 claims |
| GSKTrelegy Ellipta | $535 | $32,19836 claims |
| Lilly USA, LLCTrulicity | $43 | $15,41712 claims |
| AbbVieSynthroid | $1,038 | $1,57624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 655 internal medicine providers in Hawaii.
Other internal medicine in Kilauea
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
- James LumengHonolulu$45K
- Charles ZerezHonolulu$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.